# A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

> **NCT07634471** · PHASE2,PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 960 (estimated)

## Conditions studied

- Follicular Lymphoma

## Interventions

- **BIOLOGICAL:** MK-1045
- **BIOLOGICAL:** Rituximab
- **BIOLOGICAL:** Rituximab biosimilar
- **DRUG:** Bendamustine
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Prednisolone
- **DRUG:** Doxorubicin Hydrochloride

## Key facts

- **NCT ID:** NCT07634471
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2032-07-23
- **Final completion:** 2035-07-23
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2026-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634471, "A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07634471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*